terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 23, 2026

Warsh's Fed 'regime change' may require patience, consensus

View original at finance.yahoo.com
Warsh's Fed 'regime change' may require patience, consensus (Bloomberg) -- Kevin Warsh has vowed to usher in “regime change” as the new chair of the Federal Reserve, but Fed watchers say there are limits to how much he can revamp on his own — and that even in areas where he can make sweeping reform, it might be smarter…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • One of Warsh's primary tasks will be building FOMC consensus to lower interest rates when appropriate

    60% confidence
  • Some FOMC policymakers are pushing for the Fed to signal its next move is just as likely to be a rate hike as a rate cut

    60% confidence
  • Trump has made it no secret that he expects Warsh to lower interest rates

    60% confidence
  • If lowering rates is Warsh's top priority, he will have a strong incentive to avoid alienating FOMC members and to curry goodwill

    60% confidence
  • Warsh has vowed to usher in 'regime change' as the new Federal Reserve chair

    60% confidence
  • With inflation accelerating and the labor market stabilizing, FOMC policymakers are comfortable keeping rates on hold

    60% confidence
  • Warsh has long been an advocate for shrinking the Fed's asset portfolio

    60% confidence
  • Warsh has vowed to keep monetary policy independent from politics

    60% confidence

Data points we hold from this source

Federal Reserve · cash6.7 trillion_USD

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com